Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bouzyk

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Breast Cancer Research : BCR|July 10, 2008
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study IIHeather Spencer Feigelson, Lauren R Teras, W Ryan Diver, et al.
BMC Cancer|November 12, 2013
Wnt signaling in triple negative breast cancer is associated with metastasisNandini Dey, Benjamin G Barwick, Carlos S Moreno, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Cancer Genetics|October 14, 2017
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignanciesSandeep Mukherjee, Malini Sathanoori, Zeq Ma, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Genetica|December 29, 2004
Towards a mutant map of the mouse--new models of neurological, behavioural, deafness, bone, renal and blood disordersSohaila Rastan, Tertius Hough, Amy Kierman, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Breast Cancer Research : BCR|July 10, 2008
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study IIHeather Spencer Feigelson, Lauren R Teras, W Ryan Diver, et al.
BMC Cancer|November 12, 2013
Wnt signaling in triple negative breast cancer is associated with metastasisNandini Dey, Benjamin G Barwick, Carlos S Moreno, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Cancer Genetics|October 14, 2017
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignanciesSandeep Mukherjee, Malini Sathanoori, Zeq Ma, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Genetica|December 29, 2004
Towards a mutant map of the mouse--new models of neurological, behavioural, deafness, bone, renal and blood disordersSohaila Rastan, Tertius Hough, Amy Kierman, et al.
Pageof 2